Table A1.
Molecularly targeted agents in clinical development for the treatment of neuroblastoma.
| Target | Therapeutic Agents | Study (Reference or Clinical Trial #) |
|---|---|---|
| Aurora A | MLN8237 (Alisertib) | Mosse et al. [6], DuBois et al. [7] |
| ODC1 | DFMO | Saulnier Sholler et al. [29] NCT01586260, NCT02030964, NCT02139397 |
| mTOR | Temsirolimus | Bagatell et al. [32], Mody et al. [33] |
| Pan-PI3K/mTOR | SF1126 | NCT02337309 |
| PI3K | Copanlisib | NCT03458728 |
| AKT | Perifosine | Kushner et al. [36] |
| ALK | Crizotinib | Mosse et al. [39], NCT01606878, NCT03126916 |
| Ceritinib | NCT01742286, NCT02780128 | |
| Ensartinib | NCT03213652 | |
| Lorlatinib | NCT03107988 | |
| MEK 1/2 | Trametinib | NCT02124772, NCT02780128 |
| CDK 4/6 | Ribociclib | NCT02780128 |
| NTRK | Entrectinib | NCT02650401 |
| Larotrectinib | NCT02122913 | |
| HDAC | Vorinostat | Pinto et al. [87], DuBois et al. [88], NCT02035137 |
| BCL-2 | Venetoclax | NCT03236857 |
| BRD4 | SF1126 | NCT02337309 |